Clinical trial
A Phase III, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Safety and Efficacy of Sublingual Asenapine vs. Olanzapine and Placebo in In-Patients With an Acute Manic Episode Clinical Trial Protocol 7501004 (Secondary Title: ARES)
NCT00159744 is registered in ClinicalTrials.gov with Organon and Co as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Safety and Efficacy of Sublingual Asenapine vs. Olanzapine and Placebo in In-Patients With an Acute Manic Episode Clinical Trial Protocol 7501004 (Secondary Title: ARES)
- Lead sponsor
- Organon and Co
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 30, 2004
- Completion date
- April 29, 2006
- Enrollment
- 488 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.